Causal structure discovery methods applied to the combined SARS-CoV-2 and aging interactome show that the identified protein kinase inhibitors such as axitinib, dasatinib, pazopanib, and sunitinib target proteins that are upstream from genes that are differentially expressed in SARS-CoV-2 infection and aging, thereby validating these drugs as being of particular interest for the repurposing against COVID-19, postinfection. Here, WEE1 is linked to COVID-19.